Pure Global AI
NCT06370416Not yet recruiting

the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

A Single Arm, Exploratory Clinical Study on the Prevention of Bone Marrow Suppression Caused by Platinum Containing Chemotherapy in Advanced Non-small Cell Lung Cancer With Trilaciclib
Henan Cancer HospitalPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-small Cell Lung Cancer
Drug/Device/Intervention
Trilaciclib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Henan Cancer Hospital
Location
Zhengzhou, China
Timeline & enrollment
Phase
Phase 2
Start date
Apr 30, 2024
End date
Dec 31, 2025
Enrollment
40 participants
Primary outcome

The incidence of grade ≥ 3 neutropenia during chemotherapy treatment

Summary

This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and
 safety of tralazili before chemotherapy in patients with NSCLC.After pathological diagnosis
 of non-small cell lung cancer(NSCLC), 40 eligible subjects who met the inclusion criteria
 were screened and given a treatment regimen of trilaciclib before chemotherapy, after signing
 informed consent.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06370416
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06370416 through Pure Global AI's free database. This Phase 2 trial is sponsored by Henan Cancer Hospital and is currently Not yet recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.